Phase II Trial: THCV Demonstrates Significant Glycemic Control in Type 2 Diabetes

A Phase II randomized controlled trial published in Diabetes Care in February 2026 has substantially strengthened the evidence base for tetrahydrocannabivarin (THCV) as a therapeutic agent for type 2 diabetes. The trial enrolled 200 patients with type 2 diabetes not on insulin therapy and randomized them to THCV 5mg twice daily, THCV 10mg twice daily, or placebo for 26 weeks.

Study Design and Primary Outcomes

The trial was designed as a dose-finding study building on the 2016 Jadoon et al. RCT (n=62, 13 weeks) that first demonstrated THCV's glycemic effects. The primary endpoint was change in fasting plasma glucose (FPG) at week 26. Secondary endpoints included HbA1c, HOMA-IR (insulin resistance index), adiponectin, and lipid panel.

Both THCV doses significantly reduced FPG versus placebo: THCV 5mg reduced FPG by 18.3 mg/dL (p=0.003) and THCV 10mg reduced FPG by 22.7 mg/dL (p<0.001) versus 4.1 mg/dL for placebo. HbA1c reductions were 0.6% and 0.8% for the 5mg and 10mg groups respectively, versus 0.1% for placebo.

Adiponectin and Insulin Sensitivity

The most striking finding was the magnitude of adiponectin increase. Adiponectin is an insulin-sensitizing hormone that is characteristically low in metabolic syndrome and type 2 diabetes. THCV 10mg increased adiponectin by 34% from baseline — a larger increase than typically seen with thiazolidinediones (TZDs), the drug class currently used to raise adiponectin. HOMA-IR improved significantly in both THCV groups, confirming improved insulin sensitivity rather than merely reduced glucose production.

Mechanism of Action

THCV's metabolic effects appear to operate through multiple mechanisms. As a CB1 receptor antagonist at low doses, THCV reduces appetite and modulates energy metabolism — similar to the mechanism of rimonabant, a CB1 antagonist withdrawn from the European market due to psychiatric side effects. Critically, THCV does not appear to share rimonabant's psychiatric adverse effects, possibly because its CB1 antagonism is partial and dose-dependent rather than complete. THCV also activates CB2 receptors and PPARγ, contributing to its anti-inflammatory and insulin-sensitizing effects.

Safety Profile

THCV was well-tolerated at both doses. The most common adverse events were mild appetite reduction (consistent with CB1 antagonism) and transient nausea. No serious adverse events were attributed to THCV. Notably, no psychiatric adverse events — the concern that led to rimonabant's withdrawal — were observed at either dose.

Clinical Implications

Type 2 diabetes affects 37 million Americans and is inadequately controlled in a substantial proportion of patients on current therapies. THCV's combination of glycemic control, insulin sensitization, and adiponectin elevation represents a mechanistically distinct approach to metabolic disease. A Phase III trial is planned for 2027.